EPİTELYAL OVER KANSERLERİNDE CD24 VE CD44’ÜN İMMUNOHİSTOKİMYASAL OLARAK KARŞILAŞTIRILMASI VE PROGNOSTİK DEĞERİ Immunohistochemical Comparison of Cd-24 And Cd-44 in Epithelial Ovarian Cancer And Prognostic Values
Abstract
ÖZET
Giriş: Bu çalışmada epitelyal over kanserlerinden rezeke edilen tümör spesmenlerinde, CD 44 ve CD 24’ün ekpresyonları
analiz edilerek, bu ekspresyon ve klinikopatolojik parametreler arasındaki ilişkiyi analiz edilmiştir.
Gereç Ve Yöntemler: Bu çalışma, Kliniğimizin Jinekolojik Onkoloji Anabilim Dalı'nda tedavi edilen primer over
kanseri olan 31 hastayı içermektedir.
Bulgular: Anti-CD24 için incelenen 14 seröz karsinomlu spesmende; 6 örnekte şiddetli (+++) immünoreaktivite,
4 örnekte orta / şiddetli (++ / +++) immünoreaktivite, 2 numunede orta / şiddetli (++ / +++) immünoreaktivite,
2 örnekte hafif / orta (+ / + +) immünoreaktivite gözlendi. Bu 14 hasta CD 44 için incelendiğinde; 3
örnekte (++) modereta immünoreaktivitesi, 2 örnekte + / ++ (hafif / orta) immünoreaktivite, 9 örnekte + (hafif)
immünoreaktivite gözlendi.
Sonuç: CD44 immünoreaktivitesinin boyanma yoğunluğunun over epitelyal kanserlerinde sağkalım oranı ile
ilişkili olduğu, ancak istatistiksel olarak anlamlı olmadığı tespit edildi. Her ne kadar CD 24 sağkalımı ile ilişkinin
istatistiksel olarak anlamlı bulunmamasına rağmen, Over tümörlerde tanısal bir belirteç olarak kullanılabileceği
düşünüldü.
Anahtar Kelimeler: Cd-24; Cd-44; Immünohistokimya; Over Kanseri.
ABSTRACT
Objective: The present study evaluated the CD24 and the CD44 expression in resected tumor specimens
of ovarian carcinom and analyzed the correlation between this expression and the clinicopathological
parameters.
Material Methods: The present study included 31 patients with primary ovarian cancer who were treated in
the Department of Gynecologic Oncology of our Clinic
Results: 14 serous carcinomas examined for anti-CD24; severe (+++) immunoreactivity was observed in
6 samples, moderate / severe (++ / +++) immunoreactivity was observed in 4 samples, moderate (++)
immunoreactivity was observed in 2 samples and mild / moderate (+ / ++) immunoreactivity was observed
in 2 samples. When these 14 patients were examined for CD 44; (++) modereta immunoreactivity was
observed in 3 samples, + / ++ (mild / moderate) immunoreactivity was observed in 2 samples and + (mild)
immunoreactivity was observed in 9 samples.
Conclusion: It was determined that the staining intensity of CD44 immunoreactivity was related to the survival
rate in ovarian epithelial cancers, but it was not statistically significant. Although the association with survival
of CD 24 was not found to be statistically significant, it was thought that it could be used as a diagnostic marker
in over-tumors.
Key words: CD24; CD44; Immunohistochemistry; Ovarian tumor
References
- 1. Taşkın, L., Doğum ve Kadın Sağlığı Hemşireliği, Genisletilmis 6. Baskı, Sistem Ofset, Ankara, 553-562, 2003. 2. Adekanbi AA, Olayemi O, Okolo CA, Fawole AO, Odukogbe AT, Okani CO. Survival of ovarian cancer patients in Ibadan: clinical and pathological factors. J Obstet Gynaecol. 2014 Jan;34(1):57-9. 3. Skirnisdottir I, Seidal T, Gerdin E, Sorbe B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinom treated with adjuvant chemotherapy Int J.Gynecol Cancer2002 MayJun;12(3):265-76. 4. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer. 2004 MarApr; 14(2):259-70. 5. Muramatsu T, Mukai M, Sato S, Tajima T, Nagase E, Ikeda M, et.al. Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer. Oncol Rep. 2005 Oct;14(4):861-5. 6. Kay R, Rosten PM and Humphries RK: CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol 147: 1412-1416, 1991. 7. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T.et.al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65: 10783-10793, 2005. 8. Lim SC: CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 59 Suppl 2: S351-S354, 2005. 9. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M.et. al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89: 3385-3395, 1997 10. Sammar M, Aigner S and Altevogt P: Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. Biochim Biophys Acta 1337: 287-294, 1997
Abstract
References
- 1. Taşkın, L., Doğum ve Kadın Sağlığı Hemşireliği, Genisletilmis 6. Baskı, Sistem Ofset, Ankara, 553-562, 2003. 2. Adekanbi AA, Olayemi O, Okolo CA, Fawole AO, Odukogbe AT, Okani CO. Survival of ovarian cancer patients in Ibadan: clinical and pathological factors. J Obstet Gynaecol. 2014 Jan;34(1):57-9. 3. Skirnisdottir I, Seidal T, Gerdin E, Sorbe B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinom treated with adjuvant chemotherapy Int J.Gynecol Cancer2002 MayJun;12(3):265-76. 4. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer. 2004 MarApr; 14(2):259-70. 5. Muramatsu T, Mukai M, Sato S, Tajima T, Nagase E, Ikeda M, et.al. Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer. Oncol Rep. 2005 Oct;14(4):861-5. 6. Kay R, Rosten PM and Humphries RK: CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol 147: 1412-1416, 1991. 7. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T.et.al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65: 10783-10793, 2005. 8. Lim SC: CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 59 Suppl 2: S351-S354, 2005. 9. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M.et. al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89: 3385-3395, 1997 10. Sammar M, Aigner S and Altevogt P: Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. Biochim Biophys Acta 1337: 287-294, 1997
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Original Research |
| Authors | |
| Publication Date | March 25, 2020 |
| Published in Issue | Year 2020 Volume: 10 Issue: 1 |